Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 2/20 | 0.31 |
| ▸ | MMP9 | P14780 | 2/20 | 0.31 |
| ▸ | MMP13 | P45452 | 2/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6519257 | 0.79 | PTGER2 (0.53) | PTGER2 | |
| SCHEMBL534417 | 0.77 | CTSS (0.40) | SLC1A3SLC1A2SLC1A1PTGER2ADAM17 | |
| SCHEMBL6519267 | 0.77 | PTGER2 (0.34) | SLC1A3SLC1A2SLC1A1PTGER2ADAM17 | |
| SCHEMBL3459165 | 0.74 | PTGER2 (0.38) | SLC1A3SLC1A2SLC1A1PTGER2ADAM17 | |
| SCHEMBL533795 | 0.73 | SLC1A3 (0.35) | SLC1A3SLC1A2SLC1A1PTGER2ADAM17 | |
| SCHEMBL3459169 | 0.71 | PTGER2 (0.41) | PTGER2 | |
| SCHEMBL533797 | 0.71 | PTGER2 (0.36) | PTGER2ADAM17MMP1MMP9MMP13 | |
| SCHEMBL533073 | 0.69 | PTGER2 (0.46) | PTGER2KMT2A | |
| SCHEMBL30063042 | 0.69 | PTGER2 (0.46) | PTGER2KMT2A | |
| SCHEMBL15412005 | 0.69 | PTGER2 (0.47) | PTGER2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | SLC1A3 468/4885SLC1A2 265/4885SLC1A1 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.